Market Overview

Oncolytic Virus Cancer Therapy: 2018 Pipeline Insights with Analysis by Development Stage, Mechanism of Action, Route of Administration and Molecule Type -


The "Oncolytic
Virus Cancer Therapy- Pipeline Insights, 2018"
report has been
added to's offering.

This report outlays comprehensive insights of present scenario and
growth prospects across Oncolytic Virus Cancer Therapy.

A detailed picture of the pipeline landscape is provided with summation
of data from multiple sources with complete analysis by development
stage, mechanism of action, route of administration and molecule type.

This report provides detailed analysis of 65+ products with more than 25
companies involved. Some of the emerging products include Pexa-Vec of
Transgene/SillaJen, Telomelsin of Oncolys, and Canerpaturev (TBI-1401)
of Takara Bio.

Products covered by Phase

  • Phase III, Phase II, Phase I
  • IND
  • Pre-clinical & Discovery
  • Inactive

Overview of pipeline development activities for Oncolytic Virus
Cancer Therapy

  • Pipeline analysis of therapeutic drugs include but are not limited to
    drug description and development activities focusing on clinical and
    pre-clinical results, designations, collaborations & licensing deals,
    grants, technology and patent details.
  • Therapeutic segmentation of products for Oncolytic Virus Cancer Therapy
  • The report comprises of comparative pipeline therapeutics assessment
    by development stage, therapy type, molecule type, and administration
    route across this mechanism.


  • Provides an overview of therapeutic pipeline activity for Oncolytic
    Virus Cancer Therapy across the complete product development cycle
    including all clinical and non-clinical stages
  • It comprises of detailed profiles of Oncolytic Virus Cancer Therapy
    therapeutic products with key coverage of developmental activities
    including licensing & collaboration deals, patents issued,
    designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage,
    product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across
    Oncolytic Virus Cancer Therapy

Key Topics Covered

  1. Executive Summary
  2. Overview
  3. Introduction
  4. History of Oncolytic Virus
  5. Mechanism of Action
  6. Criteria of Selection on Oncolytic Virus for Cancer Therapy
  7. Strategies for Tumor Targeting
  8. Types of Cancer Treated
  9. Oncolytic Viruses vs Other Therapies
  10. Side effects of Oncolytic Viral Therapy
  11. Limitations of Oncolytic Viral Therapy
  12. Conclusion and Future Perspectives
  13. Pipeline Therapeutics (Active Products)
  14. Pipeline Therapeutics (Inactive Products)
  15. Comparative Analysis
  16. Late Stage Products (Phase III)
  17. Comparative Analysis
  18. Pexa-Vec: Transgene/SillaJen
  19. Product Description
  20. Research and Development
  21. Product Development Activities
  22. The list continues.
  23. Mid Stage Products (Phase II)
  24. Comparative Analysis
  25. Telomelsin: Oncolys
  26. Product Description
  27. Research and Development
  28. Product Development Activities
  29. The list continues..
  30. Early Stage Products (Phase I & IND)
  31. Comparative Analysis
  32. Pre-clinical and Discovery Stage Products
  33. Comparative Analysis
  34. Therapeutic Assessment: Active Products
  35. Assessment by Stage and Product Type
  36. Assessment by Route of Administration
  37. Assessment by Stage and Route of Administration
  38. Assessment by Molecule Type
  39. Assessment by Stage and Molecule Type
  40. Inactive Products
  41. Comparative Analysis
  42. Appendix

Companies Featured

  • SillaJen
  • Oryx
  • PsiOxus Therapeutics
  • Daiichi Sankyo
  • Vyriad
  • Genelux
  • Takara Bio
  • DNAtrix
  • Merck
  • Oncolytics Biotech
  • Oncolys BioPharma
  • Vrittu Biologics limited
  • Transgene
  • VCN Biosciences
  • CZ Biomed
  • Cell Genesys
  • Lokon Pharma

For more information about this report visit

View Comments and Join the Discussion!